Virus-Like Particle Vaccines
Bachmann, Martin F
Virus-Like Particle Vaccines - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (262 p.)
Open Access
The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation.
Creative Commons
English
books978-3-03943-075-8 9783039430741 9783039430758
10.3390/books978-3-03943-075-8 doi
Humanities
Social interaction
virus-like particle influenza A(H1N1)pdm09 vaccination pregnant women antibody titers norovirus VLP vaccine genotype pre-existing immunity cross-reactivity blocking antibodies original antigenic sin (OAS) HPVs vaccines virus-like particles (VLPs) minor capsid protein (L2) HCMV cytomegalovirus nanoparticle immune response Sudan virus mice horse purified IgG long-lived plasma cells antibodies multivalency virus-like particles antigenic analysis epitope characterization hepatitis E vaccine serological evaluation virion-like epitopes well-characterized vaccines hepatitis B virus surface (envelope) antigen sub-viral particle capsid antigen display platform viral quantification NTA flow virometry SRFM cryo-TEM SEM plant virus virus-like vaccine platform epitope antigen cat allergy Fel d 1 HypoCat™ IL-13 interleukin-13 Tfh cells cancer immunotherapy H7N9 pandemic influenza A avian flu IAV VLP vaccine n/a
Virus-Like Particle Vaccines - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (262 p.)
Open Access
The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation.
Creative Commons
English
books978-3-03943-075-8 9783039430741 9783039430758
10.3390/books978-3-03943-075-8 doi
Humanities
Social interaction
virus-like particle influenza A(H1N1)pdm09 vaccination pregnant women antibody titers norovirus VLP vaccine genotype pre-existing immunity cross-reactivity blocking antibodies original antigenic sin (OAS) HPVs vaccines virus-like particles (VLPs) minor capsid protein (L2) HCMV cytomegalovirus nanoparticle immune response Sudan virus mice horse purified IgG long-lived plasma cells antibodies multivalency virus-like particles antigenic analysis epitope characterization hepatitis E vaccine serological evaluation virion-like epitopes well-characterized vaccines hepatitis B virus surface (envelope) antigen sub-viral particle capsid antigen display platform viral quantification NTA flow virometry SRFM cryo-TEM SEM plant virus virus-like vaccine platform epitope antigen cat allergy Fel d 1 HypoCat™ IL-13 interleukin-13 Tfh cells cancer immunotherapy H7N9 pandemic influenza A avian flu IAV VLP vaccine n/a